Oxaliplatin-Based Adjuvant Chemotherapy Duration (3 vs. 6 Months) for High-Risk Stage II Colon Cancer: The Randomized Phase 3 ACHIEVE-2 Trial.

[1]  E. Oki,et al.  Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer , 2019, JAMA oncology.

[2]  Masahiro Yoshida,et al.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer , 2019, International Journal of Clinical Oncology.

[3]  R. Labianca,et al.  Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC). , 2019, Journal of Clinical Oncology.

[4]  T. Yamanaka,et al.  Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer , 2018, ESMO Open.

[5]  R. Labianca,et al.  Duration of Adjuvant Chemotherapy for Stage III Colon Cancer , 2018, The New England journal of medicine.

[6]  Masahiro Yoshida,et al.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer , 2012, International Journal of Clinical Oncology.

[7]  C. Tournigand,et al.  Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  F. D. De Braud,et al.  Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Labianca,et al.  Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  D. Shibata,et al.  Oxaliplatin-induced peripheral neuropathy’s effects on health-related quality of life of colorectal cancer survivors , 2013, Supportive Care in Cancer.

[11]  V. Lemmens,et al.  Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Kopec,et al.  Long‐term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project trials C‐07 and LTS‐01 , 2012, Cancer.

[13]  F. D. De Braud,et al.  Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  T. Hickish,et al.  Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. Labianca,et al.  Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Quasar Collaborative Group.  Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study , 2007, The Lancet.

[17]  D. Kerr,et al.  Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study , 2007, The Lancet.

[18]  D. Forman,et al.  Who to treat with adjuvant therapy in Dukes B/stage II colorectal cancer? The need for high quality pathology , 2007, Gut.

[19]  E. Van Cutsem,et al.  Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Leandri,et al.  Persistence of High-Dose Oxaliplatin-Induced Neuropathy at Long-Term Follow-Up , 2006, European Neurology.

[21]  T. Hickish,et al.  Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. , 2004, The New England journal of medicine.